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Clinical trialsDravet syndrome is a rare form of epilepsy largely refractory to current antiepileptic medications. The only pre-
cedents of randomized placebo-controlled trials in Dravet syndrome are the two small trials that led to the
approval of stiripentol. With the arrival of new clinical trials for Dravet syndrome, we sought to determine the
characteristics of the patient populationwith Dravet syndrome in Europe today, which has possibly evolved sub-
sequent to the approval of stiripentol and the ability to diagnose milder clinical cases via genetic testing. From
May to June 2014, we conducted an online parent-reported survey to collect information about the demo-
graphics, disease-speciﬁc clinical characteristics, as well as current and past use of antiepileptic medications by
European patients with Dravet syndrome. We present data from 274 patients with Dravet syndrome from 15
European countries. Most patients were between 4 and 8 years of age, and 90% had known mutations in
SCN1A. Their epilepsy was characterized by multiple seizure types, although only 45% had more than 4 tonic–
clonic seizures per month on average. The most common drug combination was valproate, clobazam, and
stiripentol, with 42% of the total population currently taking stiripentol. Over a third of patients with Dravet syn-
drome had taken sodium channel blockers in the past, and most had motor and behavioral comorbidities. Our
study helps deﬁne the current typical European patient with Dravet syndrome. The results from this survey
may have important implications for the design of future clinical trials that investigate new treatments for Dravet
syndrome.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Severe myoclonic epilepsy of infancy, also known as Dravet syn-
drome, is an epileptic encephalopathy that presents during the ﬁrst
year of life and affects 1 in 20,000 to 40,000 people [1–3]. Patients
who have Dravet syndrome display multiple seizure types including
tonic–clonic, myoclonic, absence, and focal seizures. A characteristic of
this syndrome is that seizures can be provoked by fever and visual stim-
uli and can also lead to status epilepticus [1–3]. In addition to epilepsy,
Dravet syndrome is associated with cognitive delays, behavioral disor-
ders, and an elevated risk of sudden death [1–3].
Although traditionally diagnosed according to clinical criteria, genet-
ic mutations are known to be a major cause of Dravet syndrome [4,5].
Mutations in the sodium channel-encoding gene SCN1A account for
the majority of Dravet syndrome cases [6,7] and have also been foundn Spain, Santa Fe 1, Pozuelo de
M. Aras),
dravetfoundation.eu
. This is an open access article underto causemilder forms of epilepsy, migraine, and autismwithout epilep-
sy [8–10]. Mutations in SCN1B [11], SCN2A [12], and GABRG2 [13] are
also known causes of Dravet syndrome, with additional genes such as
PCDH19 and CHD2 found to cause Dravet-like phenotypes whenmutat-
ed [14,15]. The discovery of these genes represents amajor scientiﬁc ad-
vance, making it possible to perform genetic testing of patients with
suspected Dravet syndrome that leads to the identiﬁcation and diagno-
sis of milder or clinically “atypical” Dravet syndrome cases [5,16].
Despite these major advances with regard to the genetic causes of
this rare disease, Dravet syndrome remains largely pharmacoresistant
to antiepileptic drugs [17]. After more than 30 years since its initial de-
scription, only one drug has been approved for the treatment of Dravet
syndrome (stiripentol, marketed by Biocodex as Diacomit® [18,19]).
There remains, therefore, a high need for new therapeutics able to bet-
ter control seizures as well as to preserve or improve cognition and be-
havior in Dravet syndrome.
Unprecedentedly, two new experimental drugs are expected to
start clinical trials for Dravet syndrome in Europe between 2014 and
2015: cannabidiol, developed by GW Pharmaceuticals and INSYS
Therapeutics, and fenﬂuramine, developed by Brabant Pharma. To
date, all three have obtained orphan drug designation for Dravetthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Country and genetic type of the survey population.
Country Patients SCN1Amutation
Yes No Not determined
Austria 3 2 1 0
Azerbaijan 1 1 0 0
Belgium 7 7 0 0
Czech Republic 1 1 0 0
France 22 15 3 4
Germany 30 27 0 3
Italy 50 44 5 1
Moldova 1 1 0 0
Netherlands 54 49 4 1
Poland 13 13 0 0
Portugal 10 10 0 0
Romania 10 9 0 1
Spain 59 54 3 2
Switzerland 11 11 0 0
United Kingdom 2 2 0 0
Total 274 246 16 12
Table 2
Age distribution of the survey population.
Age bands Patients %
N4 39 14
4–8 104 38
9–13 52 19
14–17 37 14
≤18 42 15
Total 274 100
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and cannabidiol developed by GW Pharmaceuticals have also obtained
the designation as an orphan drug by the European Medicines Agency.
The only precedents of randomized placebo-controlled trials in
Dravet syndrome are the two trials in France and Italy that led to the ap-
proval of stiripentol as an adjunctive treatment in Europe (2007),
Canada (2012), and Japan (2012). The two studies combined involved
65 children between 3 and 18 years of age with Dravet syndrome and
compared the efﬁcacy of stiripentol with placebo when added to the
children's existing treatment with valproate and clobazam. The use of
a very homogeneous patient population made it possible for both trials
to be strongly positive despite the small number of patients.
With the arrival of new clinical trials for Dravet syndrome, we
sought to determine the characteristics of the patient population with
Dravet syndrome in Europe today, which has possibly evolved subse-
quent to the approval of stiripentol and the ability to diagnose milder
clinical cases through genetic testing. This parent-reported survey was
set up to assess the most relevant demographic and disease-speciﬁc
clinical characteristics, to collect information on the current and past
use of antiepileptic medications by this population, and to try to deﬁne
the current “typical European patient with Dravet syndrome”.
2. Methods
2.1. Study design, assessment, and patient selection
The study was an international, voluntary, anonymous, single-
assessment, web-based survey administered by the Dravet Syndrome
Foundation Spain (http://www.dravetfoundation.eu/drugs-survey/,
see Supplemental materials). It was distributed by European organiza-
tions for patients with Dravet syndrome through the Dravet Syndrome
European Federation. The study took place from May to June 2014.
The study population consisted of patients with Dravet syndrome
identiﬁed by patient organizations through their afﬁliated distribution
lists. The questionnaire was developed in Spanish and English. Because
of the cognitive state and generally low age of the identiﬁed patients
with Dravet syndrome, the survey was completed by parents or care-
givers. No ethics approval was required because of the anonymous na-
ture of the study.
2.2. Data analysis
The data entered by responders though thewebformwere automat-
ically collected in an Excel sheet. Both the Spanish and English versions
of the surveywere collected in a single ﬁle. A total of 278 entries from15
countries were registered during the study period. After eliminating 4
duplicates, a total of 274 entries were used for the study. Data were nu-
merical (e.g., age and number of seizures) or binary (e.g., having taken
or not a speciﬁc drug) with the exception of two textboxes habilitated
for responders to input additional medications not prespeciﬁed in the
survey. The content of these boxes often corresponded to actual antiep-
ileptic drugs that the responders failed to recognize in the prespeciﬁed
list because of brand name variations between countries. These were
manually curated to populate the appropriate cells in the ﬁle. Data are
reported as total count or percentage for the different categories with-
out performing any statistical analysis. Because clinical trials often
have an inclusion criterion of minimum 4 tonic–clonic seizures per
month on average, we analyzed antiepileptic drug use both for the
total population and for this trial subpopulation.
3. Results
3.1. Demographics and clinical characteristics
Two hundred seventy-four patients from 15 European countries
were included in our study (Table 1). One hundred ﬁfty-seven patientswere male and 117 female. The highest numbers of responses were
from Spain, Netherlands, Italy, Germany, and France (Table 1). These
countries have strong patient groups and/or physicians and a relatively
high number of identiﬁed patients. The low number of UK patients in
this cohort is due to the UK patient organizations not being yet afﬁliated
with the Dravet Syndrome European Federation, which was used as
the distribution channel for the survey, and has been described by
Brunklaus et al. [20]. Genetic analysis was reported for 262/274 patients
(Table 1). Of these, the large majority (246/262) had a conﬁrmed
mutation in SCN1A, accounting for 90% of the total population. Although
the survey did not ask for mutations in other genes (see survey questions
in Supplemental materials), data from the Spanish registry of patients
with Dravet syndrome indicate that the 10% SCN1A negative population
includes patients with mutations in PCDH19, SCN1B, and SCN1B, as well
as patients with unknown genetic causes (unpublished data), with
many of the patients carrying mutations in PCDH19 choosing to become
afﬁliated with speciﬁc patient organizations. Patients were aged between
1 and 47 years, with the largest group aged 4 to 8 years (Table 2). The
adult subpopulation accounted for 15% of the responders (42/274).
Dravet syndrome is characterized by multiple seizure types, and a
minimumof convulsive seizures permonth is usually an eligibility crite-
rion for participation in clinical trials. We, therefore, asked responders
to list the average number of seizures per month that patients had, tak-
ing as a reference the last 6months (Table 3). Themost frequent seizure
typewas tonic–clonic,with 45% of the population reportingmore than 4
seizures per month, followed bymyoclonic, absence, partial, and atonic
seizures (Table 3). By countries, the percentage of patients with Dravet
syndrome with more than 4 tonic–clonic seizures per month was 26%
for France, 67% for Germany, 56% for Italy, 54% for Netherlands, and
36% for Spain. A particularly dangerous type of seizures in patients
with Dravet syndrome is status epilepticus, which can lead tomortality.
We, therefore, asked responders about the number of times that the
patients had been admitted to the emergency room as a result of status
epilepticus during the previous 12 months (Table 4). In both the total
population and the subpopulation with more than 4 tonic–clonic sei-
zures per month, one-third of the patients had one or more status
Table 3
Frequency (average per month) of different seizure types by number and percentage of
patients.
Seizure type Patients (n) %
Tonic–clonic
0 62 23
1–3 88 32
≤4 124 45
Myoclonic
0 159 58
1–3 27 10
≤4 88 32
Absence
0 173 63
1–3 38 14
≤4 66 24
Partial
0 185 68
1–3 41 15
≤4 48 18
Atonic
0 237 86
1–3 23 8
≤4 14 5
Table 5
Frequency of some nonseizure comorbidities by number and percentage of patients.
Total population
(n = 274)
Population N 4 TC
(n = 124)
Patients (n) % Patients (n) %
Disturbed sleep 128 47 67 54
Motor impairment 208 76 101 81
Abnormal socialization 179 65 83 67
Table 6
Current antiepileptic drug use by number and percentage of patients (N5% use only).
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year. Ten percent of the population (28/274) reported 4 or more emer-
gency room admissions, with numbers going up to 30 admissions per
year as a result of status epilepticus.
In addition to epilepsy, Dravet syndrome is characterized by cog-
nitive delays. The degree of cognitive delays varies from patient to
patient, although it is reported to affect the majority of patients and to
not correlate with the severity of the epilepsy [21,22]. In order to get a
better picture of the nonseizure comorbidities of Dravet syndrome,
we asked responders to report on the presence or absence of sleep dis-
turbances, motor problems, and abnormal socialization in the patients
(Table 5). Because the study measured parent-reported outcomes, the
answerswere subjective and percentagesmight vary from those report-
ed by clinicians. Responders reported an incidence of sleep problems in
nearly half of the patient population andmotor impairment in up to 76%
of the total population and 81% of the trial subpopulation (Table 5).
Two-thirds of the patients were also reported to have abnormal social-
ization (Table 5).
3.2. Current and past use of antiepileptic medications
Responders were asked to select all of the current antiepileptic
medications that the patients are taking from a list that included generic
names as well as some of the most common brand names. In total, re-
sponses included 26 different approved medications as well as two ex-
perimental ones (CBD or cannabis oil, n = 3, and fenﬂuramine, n = 1).
Each individual patient takes 0 to 6 concomitant antiepileptic medica-
tions. Only one patient was drug-free, and 14 (5%) were in monothera-
py. On average, patients with Dravet syndrome take three antiepileptic
drugs (40 and 41% in the total and trial populations, respectively), with
a large percentage taking four drugs (25 and 31%, respectively). TheTable 4
Admissions to the emergency room in the last year as a result of status epilepticus.
Total population
(n = 274)
Population N 4 TC
(n = 124)
Patients (n) % Patients (n) %
0 183 67 83 67
1 42 15 20 16
≤2 49 18 21 17most common antiepileptic drug currently used by patients with Dravet
syndrome in Europe was valproate (85%), followed by clobazam (55%),
topiramate (44%), and stiripentol (42%) (Table 6). In the subpopula-
tion with four or more tonic–clonic seizures per month, stiripentol
was the thirdmost used drug, with 51% of the population currently tak-
ing this compound (Table 6). By countries, stiripentol use in the total
population ranged from 55% in France to 31% in Netherlands, with con-
sistently higher percentages in each country when the population was
limited to those patients with four or more tonic–clonic seizures per
month (Table 7). The most common drug combination was valproate,
clobazam, and stiripentol, with or without additional antiepileptic
drugs, taken by 29% of the total population (79/274) and 35% of the
trial population (44/124).
To conclude our study, we asked responders to list all of the antiep-
ileptic medications that the patients have ever tried from the same list
used to determine their current medications (Table 8). A total of 16
antiepileptic drugs had been tried bymore than 5% of the patients in ad-
dition to the ketogenic diet. Themost commonly listed drug was leveti-
racetam, with more than half of the patients having tried it at some
point in their treatment, and over a third of the European patients
with Dravet syndrome had at some point taken the sodium channel
blockers lamotrigine and carbamazepine.
4. Discussion
4.1. The most common characteristics of the population with Dravet
syndrome
The results from our survey support that the typical European pa-
tient with Dravet syndrome is a young child with a conﬁrmedmutation
in SCN1A. Notably, only 15% of the responders included adult patients.
This is consistent with our own observations from the Spanish registry
of patientswithDravet syndromewhere 16.5%of the patient population
is over 18 years old (n = 127 patients, unpublished data). Because the
Spanish registry has been running for 5 years, this suggests that the
prevalence for the young population observed in the European survey
is not biased by the 1-month survey response period. Instead, it is likely
to accurately reﬂect the patient population afﬁliated with patient orga-
nizations, which served as our distribution channel. One potential rea-
son is that parents and caregivers are more likely to become actively
engaged with patient organizations in the years that follow their
children's diagnosis or while their children are younger. Nevertheless,
the availability of genetic tests for SCN1A and related genes hasTotal population
(n = 274)
Population N 4 TC
(n = 124)
Patients (n) % Patients (n) %
Valproate 237 86 104 84
Clobazam 151 55 77 62
Topiramate 120 44 38 31
Stiripentol 116 42 63 51
Levetiracetam 59 22 28 23
Bromide 29 11 22 18
Clonazepam 26 9 15 12
Table 7
Current stiripentol use by number and percentage of patients (countrieswithmost survey
responses).
Country Total population
(n = 215)
Population N 4 TC
(n = 104)
Patients % Patients %
France 12/22 55 4/6 67
Germany 14/30 47 10/20 50
Italy 24/50 48 16/28 57
Netherlands 17/54 31 10/29 34
Spain 20/59 34 11/21 52
Average 43 52
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the identiﬁcation of younger patients in the general population with
Dravet syndrome. An afﬁliation bias among the responders is also prob-
ably observed in the very high prevalence of patients carrying SCN1A
mutations. The increased availability of genetic tests in recent years
has led to thediagnosis of Dravet syndrome in patientswithmilder phe-
notypes, which, in the absence of a conﬁrmed SCN1Amutation, might
not havemet the criteria for a clinical diagnosis and, therefore, enriched
thepopulationwithDravet syndromewith caseswith SCN1Amutations.
In our experience, these families also become afﬁliated with organiza-
tions for patients with Dravet syndrome at a higher rate than the fami-
lies of those patients who do not have mutations in SCN1A, despite
having the same clinical diagnosis. Therefore, children and adolescents
carrying mutations in SCN1A are likely to account for the majority of
Dravet syndrome cases, with both younger age and conﬁrmed SCN1A
mutations being even more prevalent among those afﬁliated with pa-
tient organizations.
Our data also conﬁrm that the typical European patient with Dravet
syndrome has severe epilepsywithmultiple seizure types in addition to
nonseizure comorbidities. Because families with a member that has
Dravet syndrome are generally highly educated in the management of
seizures and status epilepticus, including the use of rescue medications,
the elevated frequency of emergency room admissions in these patients
reﬂects the severity of the refractory epilepsy that most patients with
Dravet syndromehave. Nevertheless, only 45% of the population reports
an average ofmore than 4 tonic–clonic seizures permonth. This number
is of particular relevance for the design of clinical trials because a mini-
mumof 4 tonic–clonic seizures is often an eligibility criterion for patient
recruitment. Such a criterion might make the recruitment of suitable
patients in a disease that has already a low incidence and that has a
high rate of underdiagnosis difﬁcult. Importantly, it would also limitTable 8
Antiepileptic drugs tried by number and percentage of patients (N5% use only).
Total population
(n = 274)
Population N 4 TC
(n = 124)
Patients (n) % Patients (n) %
Levetiracetam 139 51 78 63
Valproate 132 48 63 51
Topiramate 125 46 70 56
Clobazam 117 43 64 52
Clonazepam 100 36 58 47
Lamotrigine 95 35 57 46
Carbamazepine 92 34 47 38
Phenobarbital 78 28 41 33
Stiripentol 73 27 37 30
Ketogenic diet 47 17 33 27
Ethosuximide 42 15 25 20
Vigabatrin 36 13 27 22
Oxcarbazepin 32 12 19 15
Zonisamide 25 9 21 17
Bromide 18 7 16 13
Phenytoin 14 5 13 10
Felbamate 11 4 7 6the access of a large percentage of the populationwith Dravet syndrome
to clinical trials. Therefore, clinical trials evaluating the efﬁcacy of exper-
imental treatments in other seizure types, such asmyoclonic or absence
seizures, should be considered in Dravet syndrome.
Although our survey was focused on establishing the age distribu-
tion, seizure frequency, and antiepileptic drug use of the European
population with Dravet syndrome, all parameters used for inclusion in
clinical trials, it also serves as a proof of concept for the potential of
gathering patient data through an anonymous, web-based parent-
or patient-reported survey. Using this approach, and engaging the
collaboration of national organizations for patients with Dravet
syndrome, we were able to collect 274 individual entries over a one-
month period, a population size comparable to that of previously pub-
lished large cohorts with Dravet syndrome over a ﬁve-year study period
(e.g., Brunklaus et al., n = 241, [20]). The same survey approach could,
therefore, be used in the future to get additional insight into Dravet syn-
drome pathophysiology, such as potential genotype–phenotype corre-
lations or common electroencephalogram observations, by including
questions about genetic and electroclinical ﬁndings.
4.2. Stiripentol is widely used by the European population with Dravet
syndrome
Two of the key questions that we wanted to address regarding the
use of antiepileptic medications were (1) what are the most frequent
drugs and drug combinations used by the current European population
with Dravet syndrome and (2) howwidespread is the use of stiripentol,
the only drug approved in Europe for the management of Dravet syn-
drome. Despite having a broad repertoire of antiepileptic medications,
patients with Dravet syndrome in Europe are largely treated with only
ﬁve of these medications: valproate, clobazam, topiramate, stiripentol,
and levetiracetam, with most patients taking a combination of three
or four of these drugs. These observations support the success of the
stiripentol trials, which, seven years after stiripentol approval in
Europe, have established the valproate, clobazam, and stiripentol com-
bination as the gold standard for the management of Dravet syndrome.
The use of stiripentol was particularly high in the subpopulation with
4 ormore tonic–clonic seizures permonth. Because clinical trials are likely
to target this speciﬁc subpopulation, European trials would need to in-
clude patients taking stiripentol, despite the drug being not yet approved
in the United States, in order to appropriately capture the actual patient
population. This is also important because stiripentol has known drug–
drug interaction effects through inhibition of several cytochrome P450
isoenzymes [19] that should be clinically evaluated in combination with
any new experimental drug before the latter reaches the market.
We also noted the use of some nonconventional treatments in this
series including vagal nerve stimulation, the ketogenic diet, and the ex-
perimental drugs cannabidiol and fenﬂuramine. The more prevalent
one was the ketogenic diet, with 5% of the patients with Dravet syn-
drome currently on the diet versus 17% of patients having tried it in
the past. While the reduced number of patients on the ketogenic diet
(13/274) prevents any efﬁcacy claims, all patients were taking two to
four concomitant antiepileptic drugs and were experiencing seizures,
indicating that the ketogenic diet is likely to be only partly effective in
this population as it occurs with antiepileptic medications. A total of 5
patients in this study reported using vagal nerve stimulators, three
were taking cannabidiol or cannabis oil, and one was taking fenﬂur-
amine. All of these patients continued to have seizures and were taking
concomitant medications, including combinations of nonconventional
treatments such as vagal nerve stimulators and the ketogenic diet or
vagal nerve stimulators and cannabidiol. Although the number of pa-
tients using these nonconventional treatments in our study was too
small to make any efﬁcacy observations, both vagal nerve stimulation
and the ketogenic diet have been usedwith success in Dravet syndrome
[23–25] and fenﬂuramine and cannabidiol are the two experimental
treatments currently starting clinical trials for this population.
Fig. 1. The typical European patientwith Dravet syndrome. Summary of themost representative demographic and clinical characteristics of patients with Dravet syndrome reported in the
survey as well as the most frequently used antiepileptic medications.
108 L.M. Aras et al. / Epilepsy & Behavior 44 (2015) 104–1094.3. Sodium channel blockers
When asked about the medications that patients had taken in the
past, responders listed a number of antiepileptic drugs much larger
than the list of drugs that they are currently taking, suggesting that
after multiple trials, neurologists converge on a limited number of anti-
epileptic drugs for this population.
Interestingly, the most commonly listed drug was levetiracetam,
with more than half of the patients having tried it at some point in
their treatment. Although the potential efﬁcacy of levetiracetam in this
population has not been studied in placebo-controlled clinical trials, a
preliminary open-label report concluded that it was effective as adjunc-
tive therapy in Dravet syndrome [26] and it is a widely prescribed med-
ication for multiple types of epilepsy, therefore being considered as one
of the antiepileptic drugs recommended for this population [17,27].
Notably, over a third of the European patientswith Dravet syndrome
had at some point taken sodium channel blockers such as carbamaze-
pine. With a population with conﬁrmed SCN1A mutations in 90% of
the patients, such treatment is not recommended and can lead to dis-
ease aggravation [20,27,28]. Although our survey cannot determine
whether these drugswere administered only before or also after the pa-
tients' diagnosis of Dravet syndrome, the current number of patients
using sodium channel blockers was below 2%. This suggests that either
the lack of efﬁcacy or a Dravet diagnosis leads to the discontinuation of
these drugs. This number highlights the importance of an early genetic
diagnosis to minimize exposing patients with Dravet syndrome to sodi-
um channel blockers.
5. Conclusions
We present data from a parent-reported survey including 274 pa-
tients with Dravet syndrome from 15 European countries. This study es-
tablishes the typical European patient with Dravet syndromewho is 4 to8 years old, has a mutation in SCN1A, has epilepsy characterized by mul-
tiple seizure types but usually no more than 4 tonic–clonic seizures per
month, takes at least three antiepileptic drugs likely including stiripentol,
and has a set of comorbidities that extends beyond mental retardation
(Fig. 1). Our results stress the need to clinically evaluate any new exper-
imental drug in combination with stiripentol and to consider the poten-
tial effect that it might have – positive or negative – on the nonseizure
aspects of Dravet syndrome. We also identify that the usual trial inclu-
sion criterion of minimum 4 tonic–clonic seizures per month is likely
to reduce the already small patient population to half its size and the
evaluation of other seizure types should be considered. The results
from this studymay have important implications for the design of future
clinical trials that investigate new treatments for Dravet syndrome.
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